Alcohol Relapse and Its Predictors After Liver Transplantation for Alcoholic Liver Disease: a Systematic Review and Meta-analysis
Overview
Affiliations
Background: Alcoholic liver disease (ALD) is the leading cause of liver transplantation (LT). The magnitude and risk factors of post-LT alcohol relapse are not well described. We conducted a meta-analysis to evaluate alcohol relapse rate and its predictors after LT.
Methods: Searches of MEDLINE and SCOPUS identified eligible published studies of alcohol relapse after LT published up to 31 March 2018. Alcohol relapse was defined as any alcohol consumption post-LT, and heavy alcohol relapse was defined as a relapse of alcohol consumption that was associated with a significant harm. Data for the proportion of alcohol relapse was pooled using a meta-analysis for pooling proportion. An odds ratio (OR) of the predictor of alcohol relapse was extracted and pooled using meta-analysis for the pooling risk factor. Data were analyzed using a random effect model if heterogeneity was presented; otherwise, a fixed effect model was applied. The study was registered at PROSPERO (CRD42017052659).
Results: Ninety-two studies with over 8000 cases were recruited for pooling proportion of alcohol relapse. The alcohol relapse rate and heavy alcohol relapse rate after LT during the mean follow-up time of 48.4 ± 24.7 months were 22% (95% confidence interval (CI): 19-25%) and 14% (95%CI: 12-16%). Psychiatric comorbidities (odds ratio (OR) 3.46, 95%CI: 1.87-6.39), pre-transplant abstinence of less than 6 months (OR 2.76, 95%CI: 2.10-3.61), unmarried status (OR 1.84, 95%CI: 1.39-2.43), and smoking (OR 1.72, 95%CI: 1.21-2.46) were associated with alcohol relapse after LT. However, we noticed publication bias of unpublished negative studies and high heterogeneity of results.
Conclusions: Post-transplant alcohol relapse occurred in about one-fifth of patients who underwent alcohol-related LT. Psychiatric comorbidities represented the strongest predictor of alcohol relapse. Psychiatric comorbidities monitoring and pre-LT alcohol abstinence for at least 6 months may decrease alcohol relapse after LT.
Cigarette smoking and alcohol-related liver disease.
Lin H, Zhang J, Li M, Hou H, Wang H, Huang Y Liver Res. 2025; 8(4):237-245.
PMID: 39958918 PMC: 11771264. DOI: 10.1016/j.livres.2024.12.002.
Roldan G, Tricarico C, Brown Jr R Gastroenterol Hepatol (N Y). 2025; 20(11):662-671.
PMID: 39886332 PMC: 11775998.
Young K, Patel Y, Hoffman B, Peskoe S, Chow S, Erhart K Gastro Hep Adv. 2025; 4(1):100550.
PMID: 39811674 PMC: 11731465. DOI: 10.1016/j.gastha.2024.09.005.
Alcohol-free and low-strength drinks: friend or foe?.
Marjot T, Dhanda A Nat Rev Gastroenterol Hepatol. 2024; 22(1):3-4.
PMID: 39455889 DOI: 10.1038/s41575-024-01006-y.
Barriers to Alcohol Use Disorder Treatment in Patients with Alcohol-Associated Liver Disease.
Leko A, Leggio L Clin Liver Dis. 2024; 28(4):779-791.
PMID: 39362721 PMC: 11458136. DOI: 10.1016/j.cld.2024.06.012.